Pharmaceuticals, which contribute around 18.5% of total revenues toDutch chemicals conglomerate Akzo Nobel, produced 1.45 billion guilders ($545.7 million) sales in the second quarter of 1997, a rise of 15.2% on second-quarter 1996. Operating profits for the unit increased 16.5% to 233 million guilders. Overall group sales were 6.2 billion guilders, up 10%, with net income up 25% to 459 million guilders.
The company says that the boost in operating income at its pharmaceutical businesses was mainly due to higher volume sold by its Organon, Intervet and Diosynth units. Organon posted volume gains for its Remeron and Puregon oral contraceptives, but incurred additional costs in connection with its product launch and research activities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze